| Ytd | -91.10% | |
| 1y | -99.60% |
| Open | 1.60 | Prev Close | 1.60 | Low | 1.54 | High | 1.66 | Mkt Cap | 2.39M |
| Vol | 0.00 | Avg Vol | 2.02M | EPS | -24.50 | P/E | -0.07 | Forward P/E | N/A |
| Beta | -1.51 | Short Ratio | 1.88 | Inst. Own | 16.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 2.37 | 200-d Avg | 41.09 | 1yr Est | 0.00 |
CMND News
Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to adva
Vancouver, Canada, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearm
Vancouver, Canada, July 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clini
Vancouver, Canada, July 28, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“Clearmind” or “Compan
The Hong Kong patent application forms part of Clearmind’s exclusive worldwide licensing agreement w
Vancouver, Canada, July 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ("Clearmind") (Nasdaq:
Vancouver, Canada, July 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clini
Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potent
Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clini
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
Principal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with
Vancouver, Canada, July 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clini
Vancouver, Canada, July 07, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clini
Vancouver, Canada, June 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearm
Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearm
Vancouver, Canada, June 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearm
Vancouver, Canada, June 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearm
Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announce
US stocks down, Nasdaq drops 200 points. Dow -0.35% at 49,512.48, Nasdaq -0.93% at 25,849.08, S&
US stocks fall, Dow Jones down 0.34% & NASDAQ down 0.41% in morning trading. Home Depot reports
Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial
US stocks up as Dow Jones gains 0.48% and NASDAQ rises 0.03%. Retail sales up 1.7% in March, while p
US stocks down at midday, Dow down 0.2%, NASDAQ down 0.52%. Energy up 1.1%, consumer discretionary d
TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $1
